Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
January 2021Hsu J, et. al., Blood—Researchers presented data at the 62nd ASH Annual Meeting and Exposition on the impact of using fresh versus cryopreserved allogeneic bone marrow (BM) and peripheral blood stem cells (PBSC) grafts on patient allogeneic hematopoietic cell transplant (alloHCT) outcomes.
December 2020Maakaron J, et al., ASH abstract poster presentation, December 2020—The CIBMTR® (Center for International Blood and Marrow Transplant Research®) presented their study results suggesting that efforts should focus on minimizing residual disease and better donor selection as age alone is not a barrier to successful hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in CR1 and should not exclude patients from HCT.
December 2020Shaw B, et al., ASH oral abstract presentation, December 2020—The National Marrow Donor Program® (NMDP)/Be The Match® performed a prospective phase II study that highlighted how hematopoietic cell transplantation (HCT) with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), sirolimus, and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis was effective and expanded access to for ethnically diverse patients.
Fuchs E., et al., ASH abstract poster presentation, December 2020—When there is more than one potential haploidentical donor available, selection based on HLA considerations may improve disease free survival (DFS) and overall survival (OS). This is according to CIBMTR® (Center for International Blood and Marrow Transplant Research®) research presented at the 62nd ASH Annual Meeting.